Sharemaestro Newsreel

DaVita stock slips after Q2 revenue beats forecasts

DaVita Inc. (US23918K1088) reported strong Q2 2026 results, with revenue of $3.55 billion and adjusted EPS of $4.02, exceeding analyst expectations. Despite these positive financial figures and a 5.2% year-over-year revenue increase, the stock experienced a 1.87% decline. Analysts maintain a "Hold" rating with …

Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August By Investing.com

Zacks Research Has Positive View of OPKO Health Q3 Earnings

HC Wainwright Issues Pessimistic Forecast for NKTR Earnings

HC Wainwright Issues Optimistic Forecast for ANRO Earnings

Moderna's personalized cancer vaccine shows success in Phase 3 trial

Moderna and Merck announced that their personalized mRNA cancer vaccine achieved its primary goal in a Phase 3 trial. This success marks a significant milestone for Moderna as it seeks to expand beyond seasonal vaccines into cancer and rare disease treatments. The trial data …

Analysts Set Expectations for GYRE Q3 Earnings

Noble Financial has forecasted that Gyre Therapeutics (NASDAQ:GYRE) will report a Q3 2026 loss of $0.10 per share, with a full-year consensus estimate of a $0.30 loss per share. This follows a recent quarter where the company missed EPS expectations but exceeded revenue estimates. …

Form 8K BAXTER INTERNATIONAL INC For: 19 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by BAXTER INTERNATIONAL INC for August 19. It provides a brief financial update on the company's stock performance. The article appears to be a notice of a regulatory filing rather than an in-depth …

Haemonetics Shares Hit New 52-Week High: What's Happening?

Haemonetics Corp (NYSE: HAE) shares surged after the company announced a commercial supply agreement with CSL Plasma Inc. This agreement allows CSL Plasma to adopt Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. network, causing HAE stock to hit a new …

Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

Brookline Capital Markets has raised its Q3 2026 EPS forecast for Promis Neurosciences (NASDAQ:PMN) to a loss of $1.29 per share from a previous estimate of $2.41, while maintaining a "Strong Buy" rating. The company recently reported a quarterly loss of $1.28 per share, …

Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Neumora Therapeutics (NASDAQ:NMRA) to a loss of $0.20 from a previous forecast of $0.32, maintaining a "Buy" rating. The analyst also revised forecasts for future years, projecting narrowing losses through 2028 and profitability of …

Zacks Research Has Bearish Estimate for Omnicell Q3 Earnings

Zacks Research has issued a "Strong Sell" rating for Omnicell (NASDAQ:OMCL) and reduced its Q3 2026 EPS estimate to $0.25 from $0.27. Despite the near-term bearish outlook, Zacks projects a full-year 2026 EPS of $1.49, exceeding the broader consensus, but has lowered its FY2027 …

Wellspect Launches Surity Urinary Management System | XRAY Stock News

Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY), has launched the Surity™ Urinary Management System in the U.S. This discreet at-home urine collection device is designed to help more than 13 million Americans and their caregivers manage urinary incontinence, complementing the existing Surity™ …

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update, primarily focusing on its proposed merger with Scipher Medicine. The merger aims to advance nebokitug, a first-in-class CCL24-blocker, into a Phase 2 precision medicine trial for rheumatoid arthritis, a significant …

Galmed completes feasibility study for colon tissue assessment tech By Investing.com

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) subsidiary Colospan Ltd. has successfully completed a feasibility study for a new tissue quality assessment platform for colorectal surgery. The study, conducted on 32 colorectal cancer patients in Israel, demonstrated the viability of quantitatively measuring colon tissue compliance using an …

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte (NASDAQ: MXCT) has launched two new off-target nomination assays, CHANGE-seq-BE™ and ONE-seq-BE™, for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service. These assays aim to provide sensitive and unbiased biochemical assessment of off-target sites, with ONE-seq-BE uniquely …

MaxCyte launches base editor off-target nomination assays

MaxCyte Inc. (NASDAQ:MXCT) has introduced two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, for base editors through its SeQure service. These assays are designed to help therapeutic developers identify and prioritize off-target sites, aligning with regulatory guidance like that from the FDA on genome …

Amylyx Stock Sinks As Big Share Sale Spooks Wall Street

Amylyx Pharmaceuticals Inc. (AMLX) shares are falling due to investor reaction to the company's $350 million common stock offering. This capital raise, intended to fund pre-commercial work for avexitide, is seen as dilutive, despite strong Phase 3 data and positive analyst price target adjustments. …

Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig

AstraZeneca has halted a pivotal Phase III trial for its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC) because an independent committee determined the study was unlikely to meet its primary endpoints. This setback adds to recent disappointments for the company, …

Rapport Therapeutics (NASDAQ:RAPP) Given "Buy" Rating at BTIG Research

BTIG Research has reaffirmed a "Buy" rating on Rapport Therapeutics (NASDAQ:RAPP) with a $65 price target, suggesting a 32.63% upside. The company currently has a consensus "Buy" rating and an average target of $62.86 from other analysts. Despite insider selling, major institutional investors like …

Is Sanofi (ENXTPA:SAN) Reasonable After A 10% Three Year Slide?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Sanofi stock is coming off a mixed three year stretch, with the share price down about 10.5%, yet current valuation checks on earnings …

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com

H.C. Wainwright has reiterated a Buy rating for Citius Pharmaceuticals (NASDAQ:CTXR) with a $4.00 price target, noting that the stock is currently trading significantly below InvestingPro’s Fair Value, suggesting it may be undervalued. Despite profitability challenges, the firm projects future revenue growth for LYMPHIR, …

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

Quick Read AKTS retains full worldwide rights to its alpha-emitting cancer platform, with $517M cash and binary Q1 2027 trial data looming. NVS, whose Pluvicto grew 43% in Q2 2026, and LLY, already a $60M upfront partner, rank as the top two strategic acquirers. …

Moderna Skyrockets 90%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win

Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday. Continue Reading

Cronos Group Surges as Record Q2 Fuels Cannabis Turnaround Story

Cronos Group (TSX:CRON) saw its stock surge following a record-breaking second quarter in 2026, driven by strong international performance, particularly from its PEACE NATURALS brand in Israel, and robust sales for its Spinach brand in Canada. The company achieved its highest-ever quarterly net income …

Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com

Humacyte Inc. (NASDAQ: HUMA) announced the publication of one-year results from its V007 Phase 3 clinical trial in The Lancet Digital Health. The study demonstrated the superiority of Humacyte's acellular tissue engineered vessel (ATEV) over traditional arteriovenous fistula for hemodialysis access, especially for female …

A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis

Humacyte announced the publication of one-year results from its V007 Phase 3 trial in The Lancet Digital Health, showing superiority of its acellular tissue engineered vessel (ATEV) for hemodialysis access, especially in women and men with obesity and diabetes. This validation, along with positive …

AstraZeneca (LSE:AZN) Reports Positive Phase III Lung Cancer Trial Results

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AstraZeneca (LSE:AZN) reports positive late-stage results for TAGRISSO plus savolitinib in the SAFFRON Phase …

Merck Stock Climbs As Analysts Hike Price Targets And Pipeline Delivers

Merck & Company Inc. stock (MRK) has climbed 7.4% due to positive drug trial results and analyst price target hikes. Several major firms, including Daiwa and JPMorgan, have raised their price targets for MRK, citing strong pipeline performance and regulatory approvals for key drugs …

Baxter names a new finance chief and reiterates its 2026 outlook

Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

A new study by Avita Medical demonstrated that its PermeaDerm product reduced treatment costs by 70% compared to cadaveric allograft for temporary wound coverage, costing $148.70 versus $497.10 per 1% of total body surface area treated. The biosynthetic wound matrix also significantly cut preparation …

Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI)

Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs. Continue Reading

Baxter Appoints John Rogers Chief Financial Officer

Global medtech CFO with broad transformation and leadership experience to help advance Baxter's turnaround, financial discipline and value creation DEERFIELD, Ill., August 19, 2026--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and …

Premarket movers: Moderna jumps after Phase 3 trial; Target slides

Investing.com - Investing.com -- U.S. stock futures edged lower in Asian trading on Wednesday, pointing to a cautious start on Wall Street after major indexes closed lower for a third consecutive session, as a global bond selloff and elevated oil prices kept investors wary …

What Makes Alcon (ALC) a Bullish Bet?

Pershing Square Holdings, an investment holding company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. Pershing Square is an alternative asset manager that primarily manages capital in publicly traded investment vehicles, with 98% of its capital …